{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["brigatinib"]],"indication":"ALK-positive advanced NSCLC progressed on alectinib or ceritinib","name":"ALTA-2","nct_id":"NCT03535740","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=alta-2-nct03535740. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ALTA-2","arms":[{"description":"Brigatinib 90 mg, tablets, orally, once daily (QD) for 7 days, followed by brigatinib 180 mg, tablets, orally, QD for until objective disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by the investigator, or intolerable toxicity. Participants who experienced progression on the 180 mg dose and had not experienced toxicities greater than Grade 2 had the option to receive brigatinib 240 mg QD based on investigator's discretion, up to 20 months until data cut-off: 30 September 2020. Participants who experienced progression on any doses but judged as still benefiting from the study treatment by the investigator may continue to use the current dose, up to study end.","label":"Brigatinib 90 mg/180 mg With Optional Dose Escalation to 240 mg","type":"EXPERIMENTAL"}],"collaborators":["Takeda"],"completion_date":{"date":"2024-08-21","type":"ACTUAL"},"conditions":["ALK-positive Advanced NSCLC"],"enrollment":{"count":103,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Brigatinib","otherNames":["AP26113"],"type":"DRUG"}],"last_update":"2025-07-31","lead_sponsor":"Ariad Pharmaceuticals","official_title":"Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2020-09-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Confirmed Objective Response Rate (ORR) Using RECIST v1.1 as Assessed by the Independent Review Committee (IRC)","timeFrame":"Up to approximately 20 months from the start of enrollment till data cut-off 30 September 2020"}],"references":[{"citation":"Mok T, Nishio M, Yoshida T, Ahn MJ, Kudou K, Asato T, Yang H, Tong X, Vincent S, Zhang P, Yamamoto N, Kim ES. Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies. Lung Cancer. 2025 Nov;209:108793. doi: 10.1016/j.lungcan.2025.108793. Epub 2025 Oct 9.","pmid":"41110382","type":"DERIVED"},{"citation":"Ou SI, Nishio M, Ahn MJ, Mok T, Barlesi F, Zhou C, Felip E, de Marinis F, Kim SW, Perol M, Liu G, Migliorino MR, Kim DW, Novello S, Bearz A, Garrido P, Mazieres J, Morabito A, Lin HM, Yang H, Niu H, Zhang P, Kim ES. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). J Thorac Oncol. 2022 Dec;17(12):1404-1414. doi: 10.1016/j.jtho.2022.08.018. Epub 2022 Sep 10.","pmid":"36096442","type":"DERIVED"},{"citation":"Kim ES, Barlesi F, Mok T, Ahn MJ, Shen J, Zhang P, Ou SI. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. Future Oncol. 2021 May;17(14):1709-1719. doi: 10.2217/fon-2020-1119. Epub 2021 Feb 11.","pmid":"33569983","type":"DERIVED"}],"start_date":{"date":"2019-01-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib","url":"https://clinicaltrials.gov/study/NCT03535740"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/alta-2-nct03535740"}